Navigation Links
Johns Hopkins Kimmel Cancer Center Acquires Elekta Versa HD System
Date:9/10/2013

BALTIMORE, Sept. 10, 2013 /PRNewswire/ -- The Johns Hopkins Department of Radiation Oncology and Molecular Radiation Sciences in the Kimmel Comprehensive Cancer Center, The Johns Hopkins Hospital (Baltimore, Maryland) has acquired Elekta's Versa HD™ linear accelerator.

The radiation therapy system features the versatility to deliver high-volume conventional techniques, in addition to advanced linear accelerator treatments that require precision targeting.

Versa HD is equipped with the Agility™ 160-leaf multileaf collimator for high-speed, high-precision beam shaping to support extremely accurate tumor targeting and improved healthy tissue preservation. With previous beam-shaping technologies, high-definition (HD) beam shaping was limited to small targets. Versa HD with Agility now enables high-definition beam shaping over a significantly larger treatment field, expanding advanced treatments to a broader spectrum of tumors. Combining this novel technology with a new High Dose Rate mode, Versa HD is expected to provide rapid delivery of more sophisticated therapies within standard radiotherapy treatment times.

To learn more about Versa HD, visit www.VersaHD.com.

Versa HD is not available for sale or distribution in all markets.

For further information, please contact:
Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, email: johan.andersson@elekta.com  
Time zone: CET: Central European Time

Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, email: michelle.joiner@elekta.com
Time zone: ET: Eastern Time

About Elekta
El
'/>"/>

SOURCE Elekta
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
2. Johnson & Johnson Expects to Incur Special Charge in Second Quarter for Previously Disclosed Legal Matters
3. N.J. Woman Sues Johnson & Johnsons Ethicon Unit Over Vaginal Mesh Injuries, Says The Lanier Law Firm
4. Johnson & Johnson to Host Analyst Conference Call on Second-Quarter Results
5. GHX CEO Bruce Johnson Recognized as Ernst & Young Rocky Mountain Region Entrepreneur of the Year 2012
6. Johnson & Johnson Provides Notice Of Proposed Settlement Of Shareholder Derivative Actions, Final Settlement Hearing, And Right To Appear
7. Johnson & Johnson Announces Discontinuation of Phase 3 Development of Bapineuzumab Intravenous (IV) in Mild-to-Moderate Alzheimers Disease
8. EFJohnson Announces Impact Partner Dealer Program
9. Johnson Health Tech Statement on Lance Armstrong
10. Robert G. Savage, Former Worldwide Chairman, Johnson & Johnsons Pharmaceuticals Group, Joins Board of Nuovo Biologics, LLC
11. Johnson & Johnson Announces Plans to Establish Innovation Centers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 WHEN: Wednesday, ... Online, complimentary registration available at: http://bit.ly/1yStiU9 ... Archana Vidyasekar and Visionary Innovation Research Group ... wireless electricity, self-assembling materials, nanobots and flexible ... which will transform our lives in the ...
(Date:10/22/2014)... JOLLA, Calif. , Oct. 22, 2014 ... RGLS ), a biopharmaceutical company leading the ... microRNAs, today announced that it has demonstrated ... an ongoing clinical study evaluating RG-101, a ... the treatment of hepatitis C virus infection ...
(Date:10/20/2014)... , Oct. 20, 2014  Luoxis Diagnostics, ... MKT: AMPE), today announced that its academic collaborators ... and research potential for its novel RedoxSYS Diagnostic ... (ORP) in the body in response to injury ... of ORP as a clinical marker will be ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
... to Advance for Treatment of AllergySAN DIEGO , ... focused on the development of novel Toll-Like Receptor 8 ... inflammatory diseases, announced today that it has initiated a ... TLR8 agonist for the treatment of allergic rhinitis. The ...
... Percent of Newly Diagnosed Patients Receive a Drug Within ... New Report from Decision ResourcesWALTHAM, Mass., April 15 ... the world,s leading research and advisory firms focusing on ... that less than 30 percent of their use of ...
Cached Medicine Technology:VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis 2Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line 2Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line 3
(Date:10/22/2014)... Losing Weight Your Body’s Way , In a world ... face, it certainly can be difficult to choose the right ... favor by doing it the healthy way? Set aside the ... your body, exercise regularly, and choose foods with the most ... you need to exercise more and eat less. Despite the ...
(Date:10/22/2014)... By Steven Reinberg ... -- Infants who quickly add weight and length may be ... study suggests. In adults, certain genes have been linked ... promote proportionate gains in fat and lean muscle, the researchers ... be heavier and taller. By ages 2 and 3, however, ...
(Date:10/22/2014)... News) -- Measures taken by Firestone officials at the ... have limited the spread of the disease there and ... Natural Rubber Co. provides health services to about 80,000 ... populated communities. Between Aug. 1 and Sept. 23, ... those 80,000 people. That incidence rate of 0.09 percent ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Allegheny General ... procedure that enables physicians to repair a damaged mitral ... MitraClip system, developed by Abbott Vascular ... a progressive and life-threatening condition in which the heart’s ... to flow backward from the heart’s left ventricle into ...
(Date:10/20/2014)... October 20, 2014 hc1.com today ... secure cloud solution that enables healthcare organizations of ... ultimate healthcare-specific customer relationship management (“CRM”) solution. , ... unique needs of the healthcare industry, the hc1 ... providers and patients by combining healthcare CRM, HIPAA-compliant ...
Breaking Medicine News(10 mins):Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2
... The American Senior Fitness Association (SFA) has announced ... exercise professionals. Brain Fitness for Older Adults teaches ... incorporate effective cognitive fitness into physical activity programs, ... and mental fitness simultaneously. Details are available at ...
... This approval enables the,company to market its line of ... EU. Orthomimetics, family of products was developed,during a groundbreaking ... Massachusetts Institute of Technology . , ... helps to support the,repair of defects involving both articular ...
... National Ovarian Cancer Coalition,(NOCC) announced that body image | body ... ovarian cancer, will be on display at,the University of ... 23 to,Mar. 21, 2009. , Created ... 23 from 6 p.m. - 9 p.m. The showing ...
... at their disposable a variety of tools to research and compare ... by many cosmetic surgery seekers, followed closely by cost. The surprising ... affordable procedures. , ... Miami, FL (PRWEB) January 14, ...
... 13 Elephant Ensemble Theater, a company that brings free ... tour of The Pirate & the Squid at ... Ronald McDonald House of Long Island is a "home away ... pain of having a sick child in an area hospital. ...
... Scientific Corporation (NYSE: BSX ) will webcast ... quarter and the year ended December 31, 2008 on ... be hosted by Jim Tobin, President and Chief Executive ... Financial Officer.The live webcast and archived replay of this ...
Cached Medicine News:Health News:Brain Fitness Coming to Senior Exercise Classes 2Health News:Orthomimetics Secures CE Mark Approval for Chondromimetic 2Health News:body image body essence Exhibition Opens at University of Miami 2Health News:Savvy Healthcare Consumers Seek Skilled, Safe Cosmetic Surgeons Abroad; Cosmetic Harmony Quickly Becoming Number One Travel Destination 2Health News:Savvy Healthcare Consumers Seek Skilled, Safe Cosmetic Surgeons Abroad; Cosmetic Harmony Quickly Becoming Number One Travel Destination 3Health News:Elephant Ensemble Theater Launches New Tour at the Ronald McDonald House in Long Island 2Health News:Boston Scientific to Webcast Conference Call Discussing Fourth Quarter and 2008 Financial Results 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: